免疫检查点阻断剂治疗消化系统肿瘤研究进展  

Advances of immune checkpoint blockades in the treatment of digestive cancers

作　　者：张子瑾[1] 艾斌[1] Zhang Zijin Ai Bin(Department of Oncology, National Center of Gerontology, Beijing Hospital, Beijing 100730, China)

机构地区：[1]北京医院国家老年医学中心肿瘤内科,100730

出　　处：《国际肿瘤学杂志》2017年第1期63-66,共4页Journal of International Oncology

摘　　要：免疫检查点阻断剂是近年来恶性肿瘤治疗的研究热点，它们在消化系统肿瘤中有着不可忽视的地位。其中Nivolumab在延长晚期肝癌生存期方面超过了索拉非尼。Pembrolizumab在PD-L1阳性晚期食管癌有效率可达30％。然而易普利单抗（Ipilumumab）在晚期胰腺癌中并未看到明显疗效。然而更多的研究如Avelumab治疗晚期胃癌、Pembrolizumab治疗晚期食管鳞状细胞癌等正在进行研究中。Immune checkpoint blockade is a hot spot in treatment of cancers recently,and their effi-cacy in digestive cancer cannot been ignored.Nivolumab is superior to sorafenib in the terms of prolonging survival period for the patients with advanced live cancer.The effective rate of Pembrolizumab for advanced PD-L1 positive expression esophageal cancer can reach 30%.Nevertheless,Ipilumumab shows no significant efficacy in advanced pancreatic carcinoma.More researches are on the way,such as Avelumab in advanced gastric cancer,and Pembrolizumab in advanced esophageal squamous carcinoma.

关 键 词：消化系统肿瘤 治疗 免疫检查点阻断剂 

分 类 号：R735[医药卫生—肿瘤]